Related references
Note: Only part of the references are listed.Chronic lymohocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Eichhorst et al.
ANNALS OF ONCOLOGY (2021)
Zanubrutinib monotherapy for patients with treatment-naive chronic lymphocytic leukemia and 17p deletion
Constantine S. Tam et al.
HAEMATOLOGICA (2021)
Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib
Christian Brieghel et al.
CLINICAL CANCER RESEARCH (2021)
VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4‐YEAR FOLLOW‐UP ANALYSIS OF THE RANDOMIZED CLL14 STUDY
O. Al‐Sawaf et al.
HEMATOLOGICAL ONCOLOGY (2021)
Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry
Anthony R. Mato et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
Jan A. Burger et al.
LEUKEMIA (2020)
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Graeme A. M. Fraser et al.
LEUKEMIA & LYMPHOMA (2020)
Treatment of Chronic Lymphocytic Leukemia
Jan A. Burger
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations
Inhye E. Ahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial
Jennifer R. Brown et al.
BLOOD (2020)
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
T. D. Shanafelt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
Talha Munir et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Carol Moreno et al.
LANCET ONCOLOGY (2019)
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
Inhye E. Ahn et al.
BLOOD (2018)
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Michael Hallek et al.
BLOOD (2018)
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation
J. Malcikova et al.
LEUKEMIA (2018)
TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics
Elias Campo et al.
HAEMATOLOGICA (2018)
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
J. A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation
Lijian Yu et al.
CLINICAL CANCER RESEARCH (2017)
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia
Philip A. Thompson et al.
BLOOD (2016)
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
Kirsten Fischer et al.
BLOOD (2016)
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
Susan O'Brien et al.
LANCET ONCOLOGY (2016)
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
Mohammed Z. H. Farooqui et al.
LANCET ONCOLOGY (2015)
Mutations driving CLL and their evolution in progression and relapse
Dan A. Landau et al.
NATURE (2015)
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
Stephan Stilgenbauer et al.
BLOOD (2014)
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia
Davide Rossi et al.
BLOOD (2014)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy
JC Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Share Paper
